How costs change with infection prevention efforts by Graves, Nicholas
This is the author’s version of a work that was submitted/accepted for pub-
lication in the following source:
Graves, Nicholas
(2014)
How costs change with infection prevention efforts.
Current Opinion in Infectious Diseases, 27 (4), pp. 390-393.
This file was downloaded from: http://eprints.qut.edu.au/82098/
c© Copyright 2014 Lippincott Williams & Wilkins, Inc.
This is a non-final version of an article published in final form in Current
Opinion in Infectious Diseases: August 2014 - Volume 27 - Issue 4 - p
390–393 doi: 10.1097/QCO.0000000000000073
Notice: Changes introduced as a result of publishing processes such as
copy-editing and formatting may not be reflected in this document. For a
definitive version of this work, please refer to the published source:
http://doi.org/10.1097/QCO.0000000000000073
Costing	Infection	Prevention	Efforts	
Nicholas	Graves	
Abstract	
Nineteen	papers	were	found.	Three	described	only	the	costs	of	nosocomial	infection	and	so	
provided	limited	information	about	whether	or	not	infection	prevention	efforts		should	be	
changed.	One	was	about	the	costs	of	making	alcohol	based	hand	run	in	low	income	
countries.	Eight	papers	showed	the	extra	costs	and	cost	savings	from	changing	infection	
prevention,	and	discussed	the	health	benefits,	all	concluding	that	the	changes	were	
economically	worthwhile.	There	was	a	useful	systematic	review	of	MRSA	control	and	a	
useful	methods	paper	on	how	to	cost	prevention	efforts.	The	last	five	were	not	related	to	
hospital	infection	control.	Overall,	the	balance	has	shifted	away	from	studies	that	report	
the	high	cost	of	infections	to	more	useful	papers	that	address	the	value	for	money	of	
infection	prevention.	Good	quality	work	in	this	area	needs	to	continue	as	many	gaps	exist	
in	knowledge.		
Text	
A	search	of	PubMed	for	articles	with	the	word	“cost”	in	the	title	and	“infection	
prevention”	in	any	other	field	revealed	nineteen	papers	arising	January	2013	to	
February	2014.	Three	had	no	information	about	the	costs	of	prevention	efforts,	rather	
the	costs	of	the	health	and	clinical	consequences	of	infection	were	reported.	Kaye	et	al.	
[1]	did	a	retrospective	cohort	study	for	eight	acute	care	hospitals	matching	830	cases	of	
blood	stream	infection	to	an	equal	number	of	controls.		The	mean	extra	length	of	stay	
and	costs	attributable	to	infection	were	estimated	at	10	days	and	$43,208.		Lloyd	Smith	
et	al.	[2]	used	a	generalized	linear	model	to	estimate	attributable	costs	and	length	of	
stay	from	vancomycin‐resistant	enterococcus	in	an	acute	care	hospital	in	Canada.		They	
found	a	case	of	infection	increased	length	of	stay	by	13.8	days.	Tansarli	et	al.	[3]	
reviewed	literature	to	find	estimates	of	the	hospital	costs	arising	from	antimicrobial	
multidrug	resistance.	They	concluded	these	to	be	alarmingly	high	and	suggested	this	
was	a	justification	for	the	application	of	strict	infection	control	measures	in	medical	
institutions	with	increased	rate	of	MDR	infections.	These	papers,	and	others	like	them,	
only	partially	inform	economic	decisions	to	invest	in	infection	control	programs.	They	
only	tell	us	what	resources	or	costs	might	be	saved	by	an	effective	program.	They	fail	to	
provide	information	about	the	change	to	life	years	gained	from	making	an	investment,	
or	the	cost	of	infection	prevention	efforts.	Good	economic	decisions	require	data	on	how	
total	costs	will	change,	implementation	costs	and	cost	savings;	and	then,	how	many	life	
years,	or	quality	adjusted	life	years,	will	be	returned	for	a	the	observed	change	to	cost	
[4].	The	cost	per	life	year	gained	can	then	be	estimated	and	allows	sensible	comparison	
with	all	other	competing	programs	that	benefit	health.	These	statistics	inform	a	policy	of	
maximising	health	returns	from	scarce	resources	allocated	to	health	services.	Another	
issue	with	these	types	of	papers	is	that	the	epidemiological	methods	used	to	attribute	
cost	to	infection	mostly	fail	to	account	for	the	timing	of	the	infection	during	the	hospital	
stay.	This	has	been	shown	to	bias	upwards	the	estimates	of	attributable	cost	[5],	
providing	a	misleading	picture	of	what	costs	might	be	saved	in	infection	control	was	
expanded	[6].		
The	next	paper	was	by	Bauer‐Savage	et	al.	[7]	who	described	work	done	in	2005	by	the	
World	Health	Organization	to	develop	and	test	two	types	of	alcohol	based	hand	rub	that	
could	be	produced	locally	in	low	and	middle	income	countries.	They	concluded	the	
WHO	formulations	were	easy	and	low	cost	to	produce,	and	few	barriers	for	their	uptake	
were	raised.	This	useful	study	shows	that	improving	hand	hygiene	compliance	is	
feasible	and	potentially	low	cost	in	resource	constrained	settings.	
Next	are	eight	papers	that	show	how	costs	can	be	saved	by	making	cost	increasing	
investment	for	novel	infection	control	programmes.	Birgand	et	al.	[8]	compared	the	
costs	of	using	chromogenic	selective	medium	with	real‐time	PCR	to	detect	patient	
colonized	with	glycopeptide‐resistant	enterococci.		The	extra	costs	of	the	rapid	PCR	test	
for	GRE	detection	were	well	worth	it.	Quick	decisions	about	infection	control	were	
made,	reducing	risks,	and	also	preventing	losses	to	hospital	revenue	as	transfers	and	
new	admissions	were	not	interrupted.	This	paper	is	a	neat	example	of	how	spending	a	
little	extra	for	rapid	diagnosis	pays	for	itself,	and	presumably	reduces	risk	for	patients.	
For	this	argument	to	work	however	we	need	those	who	pay	the	extra	cost	to	enjoy	the	
cost	saving.	Budgets	in	silos	can	sometimes	stop	these	sensible	decisions	from	being	
made.	Colston	et	al.	[9]	did	a	study	in	a	1400‐bed	National	Health	Service	teaching	
hospital.	They	showed	a	policy	of	freezing	intravascular	line	tips	and	only	culturing	
them	if	there	was	a	bacteraemia	in	the	seven	days	before	or	after	the	intravascular	was	
worthwhile	on	economic	grounds.	This	new	policy	was	both	cost	saving	and	clinically	
acceptable,	and	if	widely	adopted	might	save	the	NHS	300,000	pounds	a	year.	Gurieva	et	
al.	[10]	used	a	mathematical	modelling	approach	to	show	the	costs	and	effects	of	MRSA	
screen	and	isolate	strategies.	A	decision	to	screen	patients	who	were	previously	known	
as	carriers,	possibly	combined	with	screening	of	ICU‐patients	was	found	to	be	cost	
saving	overall	when	the	estimate	of	isolation	efficacy	was	25%.		Higher	estimates	of	
efficacy	meant	more	screening	strategies	were	cost	saving.	Modelling	studies	are	
flexible	and	powerful	research	tools,	but	depend	entirely	on	the	data	and	assumptions	
used.	Another	modelling	study	was	done	by	Merollini	et	al.	[11]	to	show	the	cost‐
effectiveness	of	strategies	to	reduce	the	risk	of	surgical	site	infection	in	hip	arthroplasty.	
Using	antibiotic	impregnated	cement	in	addition	to	antibiotic	prophylaxis	was	initially	
costly,	but	due	to	the	effectiveness	there	were	reductions	in	total	costs	and	there	were	
substantial	health	benefits	for	patients.	They	made	another	important	point	by	finding	
that	laminar	air	operating‐rooms	increased	costs	dramatically,	mostly	because	risks	of	
infection	were	elevated.		This	finding	has	been	supported	by	others	[12‐16]	and	Zheng	
et	al.	(ref)	has	recently	published	a	high	quality	systematic	review	of	all	the	evidence	for	
reducing	surgical	site	infection	among	new	hips	[17].		Wintermans	et	al.	[18]	considered	
the	cost‐effectiveness	of	phenotypical	testing	that	performs	less	well	but	is	cheaper	than	
genotypical	tests	for	the	detection	of	extended‐spectrum	beta‐lactamases.	They	
concluded	more	reliable	results	reduced	unnecessary	isolation	days	and	then	
recommended	the	more	expensive	technology	be	implemented	in	the	diagnostic	
laboratory.	Zhou	et	al.	[19]	isolated	Legionella	spp.,	Pseudomonas	aeruginosa,	
Mycobacterium	spp.	and	filamentous	fungi	from	the	tap	water	of	the	Liver	Transplant	
Unit	in	a	Chinese	hospital.	They	found	point‐of‐use	water	filters	removed	the	problems	
and	that	colonisation	and	infection	with	Gram‐negative	bacteria	fell	dramatically	among	
patients.		They	suggest	the	modest	investment	in	the	filter	would	be	cost‐effective,	
although	did	not	quantify	the	changes	to	cost	and	health	benefits	from	the	adoption	
decision.	Balegar	et	al.	[20]	investigated	whether	prolonging	hang	time	of	total	
parenteral	nutrition	fluid	impacted	on	central	line‐associated	blood	stream	infection	
(CLABSI).	They	found	no	increase	in	rates	and	annual	cost	saving	using	of	AUD	
$97,603.00;	68.3%	of	nurses	in	the	study	indicated	that	their	workload	decreased	and	
80.5%	indicated	that	time	spent	changing	TPN	reduced.		
Next	found	was	a	systematic	review	of	economic	evaluations	of	control	interventions	
targeting	MRSA	in	hospitals	done	by	Farbman	et	al.	[21].	They	found	36	papers	of	which	
18	reported	the	costs	of	the	intervention	and	the	costs	saved.	The	components	of	the	
control	strategies	were	summarised	carefully,	and	estimates	were	made	of	total	
implementation	costs	in	their	review	paper.	Overall	the	studies	included	showed	a	
favourable	return	on	the	costs	of	the	prevention	programmes.	The	savings	reported	
were	seven	fold	the	costs	of	achieving	them,	and	this	does	seem	high.		Any	rational	and	
risk	neutral	person	who	was	offered	$700	in	return	for	an	investment	of	$100	would	
accept	immediately.	Yet	infection	control	professionals	have	to	fight	hard	for	their	
budgets,	let	alone	extra	investment.	Hospital	administrators	must	either	not	believe	the	
studies,	not	understand	them	or	do	not	get	to	enjoy	the	cost	savings.	There	is	a	need	to	
do	high	quality	studies	and	disseminate	them	in	terms	that	non‐researchers	understand	
and	can	critique,	so	they	have	confidence	in	the	conclusions.	There	is	also	a	need	for	
infection	control	professionals	to	protect	the	economic	savings	and	take	credit	for	them	
when	they	arise.	Reducing	infections	will	free	up	bed	days	rather	than	save	large	
amounts	of	cash	[22].	This	allows	patients	to	flow	into	the	hospital	at	a	faster	rate,	
reducing	the	average	cost	per	case	at	a	whole	hospital	level.	Cost	savings	are	only	
expressed	as	efficiency	improvements	and	not	cash	released.	A	savvy	infection	control	
professional	will	show	data	on	improved	rates	of	infection	over	time,	reduced	length	of	
stay	and	extra	admissions	to	the	hospital	because	they	prevented	cases	of	infection	[22].		
Page	et	al.	[23]	published	a	paper	about	the	methods	for	costing	infection	control	
programmes.	They	stressed	that	most	attempts	to	accurately	cost	infection	control	
programmes	presented	accounting	costs	rather	than	economic	costs.	Six	steps	were	
proposed:	to	identify	the	precise	aim	of	the	costing	study,	to	identify	whose	costs	were	
to	be	included	in	the	study,	to	establish	a	clear	picture	of	all	the	resources	needed	to	
deliver	the	infection	control	programme,	to	establish	measurement	tools	and	a	plan	for	
data	collection,	to	make	assumptions	or	rules	that	would	allow	the	costs	of	jointly	used	
resources	to	be	allocated	to	the	programme,	and	to	find	appropriate	dollar	valuations	
for	resources	that	represent	the	economic	opportunity	costs	incurred	from	adopting	the	
programme.	Their	paper	is	a	useful	guide	for	those	who	are	motivated	to	accurately	
represent	the	costs	of	an	infection	control	programme,	or	even	go	further	and	use	their	
data	in	a	full	economic	evaluation	of	an	infection	control	decision.		
Among	the	final	five	papers	found	were	studies	of	decision	support	software	[24]	and	
only	had	a	minor	reference	to	infection	control;	the	effects	on	patient	safety	of	implant	
registries	[25],	with	only	limited	application	to	infection	control;	the	cost‐effectiveness	
of	farm	interventions	for	reducing	the	prevalence	of	verocytotoxigenic	Escherichia	coli	
on	UK	dairy	farms	[26];and,		the	costs	of	investigating		patients	treated	by	a	dentist	
accused	of	serious	failures	in	infection	control	practice	[27].	
I	was	really	encouraged	by	what	has	been	published	in	2013	on	this	topic	by	the	
infection	control	research	community,	because	it	represents	an	improvement	on	what	
has	gone	before.	The	infection	control	community	has	shown	penchant	for	publishing	
information	on	the	high	costs	that	result	from	cases	of	nosocomial	infection.		There	has	
been	a	preference	to	add	as	many	noughts	onto	the	dollar	estimates	as	can	possibly	be	
justified.	It	was	millions	in	the	1970s	and	1980s,	then	it	became	billions	and	I	hope	we	
never	make	it	to	trillions	of	dollars	lost	to	nosocomial	infection.		Scepticism	arises	
because	these	big	numbers	arise	from	studies	whose	methods	biased	to	give	inflated	
results	[28,	29];	they	are	designed	to	be	alarmist	and	provoke	a	reaction	from	policy	
holders	who	hold	the	purse	strings	to	patient	safety	budgets;	and,	most	important,	is	
that	the	massive	savings	promised	are	not	realised	when	rates	actually	come	down.	This	
can	only	harm	the	credibility	of	the	community	in	the	eyes	of	policy	makers	who	are	
promised	so	much	from	investing	in	infection	control.	Much	better	is	what	we	have	seen	
published	recently.	Sensible	studies	that	consider	both	the	cost	increases	and	the	
savings,	sometime	quite	modest,	from	adopting	good	infection	control	practice	and	
sometime	new	technology	are	valuable	for	decision	making.	If	costs	are	overall	reduced	
from	making	a	change	then	there	is	no	need	to	show	the	health	benefits	in	years	of	life		
gained	or	quality	adjusted	life	years	gained,	as	they	represent	the	second	‘win’		after	a	
cost	saving	has	been	achieved.	If	however	the	cost	savings	do	not	compensate	the	cost	
increase	fully	then	the	health	returns	need	to	be	shown	and	a	cost	per	life	year	gained	
statistic	reported,	to	enable	the	value	for	money	of	infection	control	to	be	compared	to	
the	returns	from	other	uses	of	scarce	health	dollars.	Those	doing	economic	studies	in	
the	field	of	infection	control	should	always	strive	to	do	the	best	quality	research,	and	
publish	in	good	journals.	We	might	invest	in	training	programmes	for	cost‐effectiveness	
and	encourage	skills	in	economic	evaluation.	
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